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HLA haplotype-homozygous (HLA-homo) induced pluripotent stem cells (iPSCs) are being prepared to be used for allogeneic transplan-
tation of regenerated tissue into recipients carrying an identical haplotype in one of the alleles (HLA-hetero). However, it remains
unaddressed whether natural killer (NK) cells respond to these regenerated cells. HLA-C allotypes, known to serve as major ligands for
inhibitory receptors of NK cells, can be classified into group 1 (C1) and group 2 (C2), based on their binding specificities. We found
that the T cells and vascular endothelial cells regenerated from HLA-homo-C1/C1 iPSCs were killed by specific NK cell subsets from a
putative HLA-hetero-C1/C2 recipient. Such cytotoxicity was canceled when target cells were regenerated from iPSCs transduced with
the C2 gene identical to the recipient. These results clarify that NK cells can kill regenerated cells by sensing the lack of HLA-C expression
and further provide the basis for an approach to prevent such NK cell-mediated rejection responses.
INTRODUCTION
Induced pluripotent stem cells (iPSCs) have received atten-
tion as a solution to overcome the limitations of using
human embryonic stem cells (ESCs) in tissue regeneration
(Takahashi et al., 2007). To cope with the high cost and the
long duration required to develop autologous iPSCs, usage
of pre-generated allogeneic iPSCs developed from human
leukocyte antigen (HLA) haplotype-homozygous (HLA-
homo) healthy individuals has been proposed. Banking
of these iPSCs started as a national initiative in Japan in
2012, and iPSCs carrying the most frequent HLA haplo-
types in the Japanese are now available for clinical use
from the Center for iPS Cell Research and Application in
Kyoto. Tissues regenerated from these iPSCs are assumed
to trigger minimal T cell alloreactivity when transplanted
into HLA-homo and HLA haplotype-heterozygous (HLA-
hetero) recipients due to the lack of direct and indirect
recognition of HLA (Nakatsuji et al., 2008; Okita et al.,
2011; Taylor et al., 2012).
An issue remaining in the rejection of iPSC-derived tissue
in the aforementioned homo-to-hetero transplantation
setting is the allogeneic response by natural killer (NK)
cells. Clinical studies are lacking because solid organ trans-
plants in homo-to-hetero settings are often avoided to
circumvent the risk of fatal graft-versus-host disease caused
by contaminating T cells in the graft. We thus investigated
whether an NK cell-based graft rejection response against
iPSC-derived transplant tissue will occur in homo-to-het-
ero transplantation. Unique to NK cells is their ability to
sense the lack of HLA class I expression on target cells:
‘‘missing self’’ (Joncker and Raulet, 2008; Ka¨rre et al.,
1986; Nakamura et al., 2013; Suzue et al., 2001; Velardi
et al., 2009). Inhibitory receptors are responsible for
sensing ‘‘missing self’’; the killer cell immunoglobulin-
like receptors (KIRs) and the NKG2A receptor. Heteroge-
neous receptor expression generates many NK cell subsets
that differ in specificity toward HLA-A, -B, -C, and -E.
Notably, only a fraction of these NK cell subsets in periph-
eral blood acquire the ability for missing-self response, a
process termed ‘‘licensing’’ or ‘‘education,’’ whereby it is
hypothesized that the cells that have encountered cognate
receptor-HLA class I ligand interactions during cellular
development become capable of mounting missing-self
responses (Anfossi et al., 2006; Kim et al., 2005).
All HLA-C molecules are ligands for inhibitory KIRs
(KIR2DL1, 2, 3), whereas only HLA-A, and -B allotypes that
carry the Bw4 motif are recognized by KIR (KIR3DL1)
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(Moesta and Parham, 2012). The HLA-C allotypes are classi-
fied into twogroups basedon their sequence: ‘‘C1’’ and ‘‘C2’’
ligands (Moffett and Colucci, 2015). Based on their HLA-C
genotypes, graft recipients are therefore divided broadly
into C1/C1, C1/C2, and C2/C2 types. It is predicted that
when regenerated cells from HLA-homo-C1/C1 or -C2/C2
iPSCs are transplanted into anHLA-hetero C1/C2 recipient,
the recipient’s licensedNK cellswill respond against the lack
of the KIR ligand (HLA-C2 or -C1, respectively) on the trans-
plant and eventually kill the graft due to the lack of inhibi-
tory signaling from KIR2DL1 or KIR2DL3, respectively,
following the conventional mechanism of missing self
unique to NK cells. Here, the missing-self response is
thought to be a result of the lack of inhibitory signaling in
the presence of activating receptor engagement.
To test whether iPSC-derived cells will undergo such NK
cell-based killing, we first established iPSCs from an HLA-
homo-C1/C1 healthy volunteer and produced T cells as
well as vascular endothelial (VE) cells to be used as target
cells in co-culture assays. This is because (1)we are planning
to use iPSC-derived cytotoxic T cells for cell therapy against
cancer (Maeda et al., 2016; Vizcardo et al., 2013), and (2) VE
cells will likely become the first target of NK cells in periph-
eral circulation, as exemplified by NK cell-based vasculop-
athy in an allogeneic cardiac transplantation mouse model
(Uehara et al., 2005). As effector cells of putative recipients,
we usedNK cells collected fromHLA-hetero-C1/C2 healthy
volunteers. We found that in this setting, NK cells exerted
cytotoxicity against iPSC-derived cells, and that this is
dependent on missing-self recognition.
RESULTS
In the present study, we tested whether regenerated tissue/
cells developed from HLA-homo iPSCs can be rejected by
NK cells when transplanted into an HLA-hetero recipient.
To this end, we selected three healthy volunteers, one puta-
tive donor and two putative recipients (Figure 1A). The first
donor was homozygous for the second frequent HLA
haplotype in the Japanese population (A*3303, B*4403,
C*1403, DR*1302). As HLA-C*1403 is group 1 HLA-C,
this individual was designated HLA-homo-C1/C1,
‘‘Homo-A.’’ The other two individuals carried the same
HLA haplotype on one allele as Homo-A; i.e., in a haploi-
dentical setting, one individual bearing group 2 HLA-C
on the other allele (HLA-hetero-C1/C2, ‘‘Hetero-1’’), and
the other individual carried different group 1 HLA-C on
the other allele (HLA-hetero-C1/C1, ‘‘Hetero-2’’). We did
not include Bw4 ligand in this case, since this common
HLA haplotype carries the Bw4 ligand (B*4403). In the
following experiments, we produced iPSCs from Homo-A
and Hetero-1, and the pluripotency of established iPSCs
(clone: Homo-A#1, Hetero-1#1, #4) were characterized
(Table S1). Cells regenerated from those iPSC lines were
used as target. As effector cells, NK cells in peripheral blood
mononuclear cells (PBMCs) collected from Hetero-1 or
Hetero-2 were used.
NK Cells Are Tolerant to the T Cells and VE Cells
Regenerated from Autologous iPSCs
We first tested whether NK cells respond to autologous
(Auto) iPSC-derived cells. This experiment was designed
as a human version of a previous report in mouse, whereby
cardiomyocytes (CMs) regenerated from ESCs were not
killed by NK cells from syngeneic mouse (Frenzel et al.,
2009). iPSCs were produced from peripheral CD8 T cells
collected from donor Homo-A (Figure 1B). From the iPSCs,
T cells and VE cells were regenerated as target cells (desig-
nated iPSC-TCs or iPSC-VEs, respectively) using established
methods (Maeda et al., 2016; Masumoto et al., 2014).
The resulting iPSC-TCs were CD4CD8+TCRab+ cells
Figure 1. NK Cells Do Not Respond to Cells Regenerated from Autologous iPSCs
(A) HLA typing and KIR ligand classification of the cells used to derive iPSCs (Homo-A) and the donors from which NK cells were isolated
(Hetero-1, Hetero-2). The shared haplotype is depicted in orange.
(B) Schematic illustration of the experimental procedure. iPSCs were produced from CD8+ T cells isolated from Homo-A. T cells or vascular
endothelial (VE) cells regenerated from the iPSCs were co-cultured with NK cells collected from donor Homo-A, and the activation status of
NK cells or cytotoxicity against regenerated cells was assessed.
(C) Representative flow-cytometric profiles of the T cells (TCs) derived from Homo-A iPSCs.
(D) A flow-cytometric profile of iPSC-derived VE cells from Homo-A.
(E) Flow-cytometry-based profiling of HLA class I expression on primary CD8+ T cells, Homo-A iPSC-derived T cells (iPSC-TCs), and VE cells
(iPSC-VEs).
(F–H) NK cell activation status (CD107a mobilization assay and intracellular staining for IFN-g) was assessed on Homo-A derived NK cells
after 12 hr of co-incubation with autologous (Auto) iPSC-derived cells, an HLA class I-deficient leukemic cell K562 (positive control), and
Auto PBMCs (negative control). (F) Representative flow-cytometry analysis using the CD107a mobilization assay (top) and intracellular
staining for IFN-g (bottom). (G and H) Homo-A-derived NK cells did not respond to Auto iPSC-TCs (G) and Auto iPSC-VEs (H) in terms of
cytotoxicity (left; CD107a) and cytokine production (right; IFN-g) compared with the response against Auto PBMCs.
(I and J) Eighteen-hour 51Cr-release cytotoxicity assays using Homo-A NK cells against Auto iPSC-TCs (I) or Auto iPSC-VEs (J).
Results are presented as mean ± SD from three independent experiments. **p < 0.01, ***p < 0.001, Student’s t test. n.s., not significant.
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(Figure 1C), and iPSC-VEs were CD31+VE-Cadherin+ cells
(Figure 1D). These cells expressed HLA class I at levels com-
parable with that of primary CD8 T cells (Figure 1E).
NK cell responses were then assessed in co-culture assays
using Auto iPSC-TCs as target. Cytotoxicity and cytokine
responses were measured using the CD107a mobilization
assay and intracellular staining for interferon-g (IFN-g),
respectively. As anticipated, the NK cells were hyporespon-
sive to Auto iPSC-TCs at levels similar to those of Auto
PBMCs (Figures1Fand1G)andofAuto iPSC-VEsaswell (Fig-
ure 1H). The lack ofNK cell responses against Auto iPSC-TCs
and-VEswerevalidated furtherwithacytotoxicityassay; the
NK cells did not exhibit cytotoxic activity against either
Auto iPSC-TCsor -VEs (Figures 1I and1J).Very similar results
wereobtainedwhentarget cells fromHetero-1-derived iPSCs
and NK cells from Hetero-1 were used (Figure S1). These
results indicate that humanNK cells do not respond to cells
‘‘regenerated’’ from autologous iPSCs.
NK Cells Are Capable of Mounting a Missing-Self
Response against Regenerated T Cells and VE Cells in a
KIR-Ligand-Mismatched Setting
We next examined whether NK cells have the potential to
reject regenerated, allogeneic cells when KIR ligands are
mismatched in a putative ‘‘homo-to-hetero’’ setting. Again,
Tcells or VE cells were regenerated from iPSCs derived from
donor Homo-A (Homo-A iPSC-TCs or Homo-A iPSC-VEs)
(Figure 2A). NK cells from donors Hetero-1 (mismatched)
or Hetero-2 (matched) were used as effector cells.
NK cells from Hetero-1 displayed significant cytotoxicity
against Homo-A iPSC-TCs at a 10:1 effector-to-target (E/T)
ratio and at both the 6- and 18-hr time points (Figures 2B
and 2C), whereas such specific lysis was absent with NK
cells from donor Hetero-2 (Figure 2D). NK cells from Het-
ero-1 or Hetero-2 displayed the same pattern of response
against VE cells regenerated from Homo-A-derived iPSCs
(Homo-A iPSC-VEs) (Figures 2E and 2F). These results
were further verified by phase-contrast microscopy
whereby VE cell death was observed in co-culture with Het-
ero-1 NK cells but not with Hetero-2 NK cells (Figure 2G).
The conclusion is that the NK cells from an HLA-C1/C2
person elicit cytotoxicity against C1/C1 iPSC-derived cells,
whereas NK cells from an HLA-C1/C1 person do not. These
results support our prediction that NK cells have the capa-
bility to mount a rejection response against iPSC-derived
grafts through missing-self recognition.
NK Cell Licensing Is a Key Factor in Cytotoxicity
against Cells Regenerated from iPSCs
The results presented so far imply that NK cells are able to
sense the absence of a KIR ligand in regenerated cells via
the ‘‘missing-self recognition’’ mechanism. If this is the
case, the NK cells that express inhibitory KIR for the
missing ligand should be exclusively responsible for this
killing. Taking KIR2DL1 and its ligand HLA-C2 as
example, we approached this question by comparing
the responses of four NK cell subsets expressing combina-
tions of KIR2DL1 and KIR2DL3: KIR2DL3+2DL1,
KIR2DL3+2DL1+, KIR2DL32DL1+, and KIR2DL32DL1
(R1, R2, R3, and R4), respectively. The expectation is
that NK cell subsets R2 and R3 that express KIR2DL1
will become exclusively activated upon encountering
target cells of the C1/C1 genotype.
NK cells fromdonorHetero-1 (homozygous for the group
AKIRhaplotype and thus carries theKIR2DL1 andKIR2DL3
genes but not the KIR2DL2 gene [Figure 3A]) (Yawata et al.,
2002) were co-cultured with Homo-A iPSC-TCs. Consistent
with the results shown in Figure 2B, we found a significant
increase in CD107a+ cells and IFN-g+ cells within the bulk
NK cells (Figure 3B). When these NK cells were subdivided
into R1–R4 subsets (Figure 3C), the R2 and R3 subsets both
displayed allogeneic responses in terms of proportion and
absolute number of CD107a+ cells and IFN-g+ cells after
co-culture with Homo-A iPSC-TCs (Figures 3D, 3E, S2A,
and S2B). No significant increase of CD107a+ cells nor
IFN-g+ cells was seen in the other NK cell subsets (Figures
3D and 3E), indicating that sensing of missing self and
licensing involving the KIR2DL1 receptor-ligand interac-
tion was the primary mechanism inducing alloreactivity
against the iPSC-derived cells. In addition, we co-cultured
Hetero-2 NK cells (homozygous for the group A KIR haplo-
type) (Figures 3A and 3F) with Homo-A iPSC-TCs, where no
KIR-ligand mismatch takes place, and investigated the
proportion of CD107a+ cells and IFN-g+ cells of NK cells
Figure 2. NK Cells from HLA-Hetero C1/C2, but Not C1/C1, Exhibit Cytotoxic Activity against Regenerated T Cells and VE Cells
Derived from HLA-Homo C1/C1 iPSCs
(A) Schematic illustration of the experimental procedure. iPSCs were produced from Homo-A, and subsequently T cells (Homo-A iPSC-TCs)
or VE cells (Homo-A iPSC-VEs) were regenerated. Cytotoxicity against the regenerated cells was assessed in co-culture assays with NK cells
isolated from Hetero-1 (C1/C2) or Hetero-2 (C1/C1).
(B–F) Cytotoxicity assays (B, 6 hr; C–F, 18 hr) of NK cells isolated from donors Hetero-1 or Hetero-2 against Homo-A iPSC-TCs and -VEs.
(G) Phase-contrast microscopy images of iPSC-VEs after co-culture with allogeneic NK cells display the presence of apoptotic iPSC-VEs
(arrowheads). NK cells are indicated by arrows. The iPSC-VEs were plated on a 96-well plate and co-cultured with NK cells collected from
Hetero-1 (middle) or Hetero-2 (right) at a 4:1 E/T ratio for 24 hr. Scale bars, 50 mm.
Results are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.
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Figure 3. KIR2DL1+ NK Cell Subsets Isolated from a C1/C2 Donor Respond to Regenerated C1/C1 T Cells or VE Cells
(A) The KIR genotypes for the two donors from which NK cells are isolated are shown. The full and deleted forms of KIR2DS4 are indicated
by an F and D, respectively.
(B) NK cells isolated from a donor Hetero-1 were co-cultured for 12 hr with Homo-A iPSC-TCs and Auto iPSC-TCs.
(C) The variegated expression of KIR2DL1 and KIR2DL3 generates four distinct cell subsets (R1 to R4) within the CD3CD56+ NK cells
isolated from Hetero-1.
(legend continued on next page)
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in the R1–R4 subsets. No significant increase of CD107a+
cells nor IFN-g+ cells was seen in any subset (Figure 3G),
indicating that the NK cells expressing KIR2DL1 in this in-
dividual with the C1/C1 genotype had not been licensed to
respond to the absence of C2, and were thus hyporespon-
sive to iPSC-derived cells carrying the C1/C1 type.
This hypothesis was further supported when NK cells
collected from Hetero-1 and Hetero-2 were co-cultured
with Homo-A iPSC-VEs. The same R2 and R3 NK subsets
of Hetero-1 were the primary responders against the target
cells (Figures 3H and 3I) whereas theNK subsets of Hetero-2
did not respond (Figure 3J), indicating that the NK cells
expressing KIR2DL1 in a C1/C2 heterozygote are exclu-
sively activated when they encounter regenerated cells
with the C1/C1 genotype. This infers that the results in
Figures 2B, 2C, and 2E are based on recognition of missing
self and NK cell licensing.
As a confirmation, we performed a cytotoxicity assay
using KIR2DL1 cells (R1 + R4 subsets) or KIR2DL1+ cells
(R2 + R3 subsets) isolated by magnetic beads (Figure 4A,
purity >95%) as effector cells, and Homo-A iPSC-TCs and
Auto iPSC-TCs as targets. In agreement with the previous
results, the R1 + R4 cells were hyporesponsive to both types
of target cells but were able to kill K562 cells (Figure 4B). In
contrast, the R2 + R3 cells showed significant cytotoxicity
against Homo-A iPSC-TCs but not against Auto iPSC-TCs
(Figure 4C). Thus in this reductionist experiment, it is the
NK cell subsets expressing inhibitory KIR for the group
2 HLA-C ligand that exert cytotoxicity against the regener-
ated C1/C1 cells.
(D and E) Twelve-hour co-incubation assay by using Homo-A iPSC-TCs as target cells. CD107a+ (D) and IFN-g+ (E) cell numbers are shown in
right panels.
(F) The R1–R4 subsets within the NK cells isolated from donor Hetero-2, as defined by the expressed combinations of KIR2DL1 and
KIR2DL3.
(G) Twelve-hour co-culture assay by using Homo-A iPSC-TCs as target cells. NK cells were isolated from donor Hetero-2.
(H–J) Twelve-hour co-culture assay by using Homo-A iPSC-VEs as target cells. NK cells were isolated from donor Hetero-1 (H and I) and
Hetero-2 (J). CD107a+ (H) and IFN-g+ (I) cell numbers are shown in right panels.




Figure 4. Cytotoxic Responses against Regenerated C1/C1 T Cells Is Limited to the KIR2DL1+ NK Cell Subsets Isolated from a C1/C2
Donor
(A) Flow-cytometric profiles of KIR2DL1 and KIR2DL3 in NK cells isolated from donor Hetero-1 after sorting by magnetic beads. KIR2DL1
cells (R1/R4) were enriched by negative selection (depletion of KIR2DL1+ cells), whereas KIR2DL1+ (R2/R3) cells were enriched by positive
selection.
(B and C) Six-hour cytotoxicity assays of NK cells isolated from donor Hetero-1 against Homo-A iPSC-TCs. Results are presented as mean ±
SD from three independent experiments. *p < 0.05, **p < 0.01, Student’s t test.
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Figure 5. Ectopic Expression of the HLA-C2 Molecule in T Cells and VE Cells Regenerated from iPSCs Suppresses NK Cell
Alloreactivity
(A) Schematic illustration of the experimental procedure. Homo-A-derived C1/C1 iPSCs were transduced to express group 2 HLA-C, using a
lentiviral construct encoding UbC-HLA-C*04:01-IRES-Venus (Homo-A C0401+ iPSCs). As a control, Homo-A iPSCs transduced with a group
1 HLA-C gene was also produced (Homo-A C0102+ iPSCs). T cells and VE cells were regenerated from the Homo-A C0401+ iPSCs and used as
target cells.
(B) Flow-cytometric analysis indicated a homogeneous high expression of Venus in Homo-A C0401+ iPSCs and Homo-A C0102+ iPSCs.
(legend continued on next page)
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Overexpression of a Missing KIR Ligand Enables NK
Cell Tolerance against Cells Regenerated from
Allogeneic iPSCs
We then proceeded to investigate whether the alloreactiv-
ity that could lead to a graft rejection response can be
antagonized by overexpression of the C2 ligand on target
cells. For this purpose, and to alleviate an alloreactive
T cell response at the same time, we transduced Homo-A
iPSCs with a group 2 HLA-C allotype that is identical to
the recipient.
Thus, we lentivirally transduced Homo-A iPSCs with the
HLA-C*04:01 (‘‘C0401’’) gene together with theVenus gene
as a reporter (Figure 5A). As a negative control, we trans-
duced Homo-A iPSCs with a group 1 HLA-C allotype,
HLA-C*01:02 (‘‘C0102’’). The resulting cells (designated
Homo-A C0401+ iPSCs and Homo-A C0102+ iPSCs) were
found to express Venus (Figure 5B). We then regenerated
T cells from these iPSCs (designated Homo-A C0401+
iPSC-TCs and Homo-A C0102+ iPSC-TCs) and co-cultured
them with NK cells isolated from Hetero-1. Here we
observed that the ectopic expression of the C2 ligand on
Homo-A iPSC-TCs efficiently blocked the cytotoxicity of
NK cells, as specific lysis did not increase against Homo-A
C0401+ iPSC-TCs (Figure 5C). Furthermore, the cytotox-
icity against Homo-A C0102+ iPSC-TCs was at a level
comparable with that against Homo-A iPSC-TCs (Fig-
ure 5C), indicating that the blockade of cytotoxicity
against Homo-A C0401+ iPSC-TCs was unlikely to be sim-
ply due to the overexpression of the HLA-C gene. The
experiments using regenerated VE cells as target cells
resulted in the same observation (Figure 5D).
The specificity of blockade by HLA-C allotypes was
confirmed by comparing the suppression of NK cell sub-
sets defined by the expression of KIR2DL3 versus
KIR2DL1. The upregulation of CD107a and increased
intracellular IFN-g production observed in the aforemen-
tioned experiments against Homo-A C0401+ iPSC-TCs or
Homo-A C0401+ iPSC-VEs was reduced to the level of
the autologous control (Figures 5E and 5F). These results
are in line with those from a previous study in which
NK cells expressing inhibitory KIR for self HLA ligands
are silenced by target cells enforced to express correspond-
ing KIR ligands (Yu et al., 2007).
Collectively, these results provide compelling evidence
that the cytotoxic activity of NK cells against iPSC-derived
regenerated cells depends on recognition of the missing
self. Moreover, the method for overexpression of HLA
has potential for clinical application to circumvent NK
cell-mediated immune responses in KIR-ligand-mis-
matched transplantation.
NK Cells Respond to VE Cells Regenerated from an
iPSC Line Homozygous for the Most Frequent HLA
Haplotype in Japanese
To confirm our hypothesis in other HLA haplotypes, we
investigated NK cell alloreactivity in the co-culture assays,
using as target cells the iPSC line homozygous for the
most frequent HLA haplotype in the Japanese population,
namely 454E2 (Figure 6A) (Okita et al., 2011). NK cells were
isolated from three healthy volunteers bearing the same
HLA haplotype on one chromosome, hereafter designated
‘‘Hetero-3,’’ ‘‘Hetero-4,’’ and ‘‘Hetero-5.’’ Donors Hetero-3
and Hetero-4 were of C1/C1 genotype, while Hetero-5
was of C1/C2 genotype. Donors Hetero-3, Hetero-4, and
Hetero-5 were KIR group A homozygotes (Figure S3A).
Target cells were prepared by regenerating VE cells from
454E2 cells (454E2-VEs). NK cells were isolated from
donors Hetero-3 or Hetero-4, and their responses quanti-
fied in co-culture assays. As anticipated from the previous
experiments, NK cells exhibited little cytotoxic activity
against 454E2-VEs (Figure 6B), regardless of whether they
were KIR2DL1-positive or -negative (Figures S3B–S3D).
Slightly increased levels of specific lysis were observed
whenNK cells fromHetero-5were used as effector cells (Fig-
ure 6C), likely due to the licensing through the extra KIR
ligand (group 2 HLA-C).
We then performed C2-overexpression experiments by
transducing 454E2 cells with HLA-C*15:02 (C1502). Simi-
larly, VE cells expressing C*15:02 (C1502+ 454E2-VE cells)
were regenerated from 454E2, and co-culture assays were
conducted using NK cells collected from Hetero-5. NK cell
subsets were defined by the expressed combinations of
KIR2DL1 and KIR2DL3 (Figure 6D), and responses were
compared between subsets to enable assessment of HLA-
specific NK response mechanisms. In the positive control
(Figure 6E, dark blue bars), the results agreed with those
from the previous experiments that indicated cytotoxicity
and proinflammatory cytokine responses exclusively in the
R2 and R3 NK cells. This exclusive response against 454E2-
VEs by the R2 and R3 NK cells from donor Hetero-5 was
suppressed when C1502+ 454E2-VEs were used as target
cells (Figure 6E, green bars), demonstrating the efficacy of
our KIR-ligand-transduction approach in inducing NK
cell tolerance against tissue regenerated from iPSCs.
Finally, we enriched KIR2DL1 or KIR2DL1+ NK cells
from donor Hetero-5 and used these cells in cytotoxic
(C and D) Results from 6-hr cytotoxicity assays using NK cells isolated from donor Hetero-1 against T cells (C) and VE cells (D) regenerated
from Homo-A C0401+ iPSCs.
(E and F) Twelve-hour co-culture assay by using Homo-A C0401+ iPSC-TCs (E) and -VEs (F) as target cells.
Results are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.
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Figure 6. KIR-Ligand-Mismatched NK Cells Respond to VE Cells Regenerated from iPSCs Homozygous for the Most Frequent HLA
Haplotype in Japanese
(A) HLA haplotypes and KIR ligands of an iPSC line (454E2) and those of three blood donors. The 454E2 line is homozygous for the most
frequent HLA haplotype in Japanese (shaded in blue), and the blood donors are all heterozygous for this haplotype. Note that donor Hetero-5
is the only source of NK cells that carries the group 2 HLA-C ligand, so the KIR2DL1+ NK cells are licensed only in this donor within the panel.
(B and C) Eighteen-hour cytotoxicity assay of NK cells collected from (B) Hetero-3 (C1/C1), Hetero-4 (C1/C1), and (C) Hetero-5 (C1/C2).
(D) The R1–R4 subsets within the NK cells isolated from donor Hetero-5, as defined by the heterogeneous expression of KIR2DL1 and
KIR2DL3.
(E) Twelve-hour co-culture assay using NK cells isolated from Hetero-5.
(F and G) Eighteen-hour cytotoxicity assays of NK cells isolated from Hetero-5 against 454E2-VEs. The KIR2DL1-positive and -negative NK
cell subsets were isolated from Hetero-5 using magnetic beads.
Results are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.
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assays, targeting 454E2-VEs. As anticipated, KIR2DL1 NK
cells did not exert specific lysis against 454E2-VEs (Fig-
ure 6F). In contrast, KIR2DL1+ NK cells exhibited cytotoxic
activity against 454E2-VEs; however, this response was
suppressed when C1502+ 454E2-VEs were used as target
cells (Figure 6G), indicating that KIR2DL1+ NK cells are
exclusively responsible for the observed cytotoxicity of
NK cells against 454E2-VEs, and that such killing is based
on missing-self recognition.
DISCUSSION
Generating iPSCs for individual persons with various HLA
backgrounds is now readily achieved, and it has been
assumed that allogeneic immune responses can be circum-
vented in transplant using autologous iPSC-derived tissue.
However, the cost and the long duration for iPSC develop-
ment are obstacles, and thus the clinical solution is to bank
and utilize HLA-homozygous iPSCs for tissue regeneration
with the goal of haploidentical allogeneic transplantation.
Thepresent studydemonstrates thatNKcells can respond
to KIR-ligand-mismatched iPSC-derived regenerated cells
in vitro, and that the mechanisms are through the
missing-self recognition response distinct to NK cells.
Therefore, careful consideration should be given to NK
cell alloreactivity in the case of KIR-ligand-mismatched
transplantations of iPSC-derived cells. This is because trans-
plantation in this context is planned in the near future in
Japan, and clinical trials will soon be conducted globally.
We further propose a method that has potential to prevent
possible rejection responses by NK cells, whereby an HLA
class I gene is ectopically expressed in cells regenerated
from iPSCs to cancel the missing-self NK cell responses.
In this study, we first approached the question as to
whether NK cells have the potential to reject iPSC-derived
‘‘hematopoietic’’ cells. This is of particular relevance in
utilizing regenerated T cells in cell therapy (Maeda et al.,
2016; Themeli et al., 2013), which will be applied in alloge-
neic settings in the near future. Through our experiments,
it is clear that iPSC-derived T cells are killed by NK cells in a
KIR-ligand mismatch situation.
Our second question centered on whether allogeneic
iPSC-derived tissues/organs other than hematopoietic cells
could be attacked by NK cells. NK cells play a role in graft
rejection of solid organs in mouse and human (Harmon
et al., 2016; Villard, 2011). In a murine parent-to-F1 hybrid
cardiac transplantation model, NK cells exerted graft rejec-
tion in collaboration with CD4+ T cells (Uehara et al.,
2005). In human, biopsy samples of cardiac allografts
showed infiltration of NK cells that was likely involved in
allograft rejection (Sorrentino et al., 2006). Some other
studies have shown that KIR-ligandmismatch is associated
with allograft rejection in renal (van Bergen et al., 2011)
and liver transplant (Legaz et al., 2013).
In this context, in the present study we have demon-
strated that NK cells can kill iPSC-derived VE cells. This
result is important, since VE cells will be initially exposed
to NK cells when transplanted. Indeed, it was previously
demonstrated in the aforementioned model of murine
parent-to-F1 cardiac transplantation that NK cells initially
cause vasculopathy in the allograft, which eventually leads
to rejection of the graft (Uehara et al., 2005). In regenera-
tive medicine, some studies are trying to produce 3-dimen-
sional structures containing vasculature (Takebe et al.,
2013). The potential for NK cell alloreactivity against VE
cells would become a serious issue when such approaches
are realized.
Another consideration affecting the fate of the iPSC-
derived graft is the environment into which the regener-
ated tissue is transplanted. In transplant of iPSC-derived
CMs (Kawamura et al., 2016; Shiba et al., 2016) and retinal
pigmentation membrane (RPM) (Sugita et al., 2016) in
monkey models, immune reactions were dramatically
reduced in the homo-to-hetero setting as compared with
major histocompatibility complex total-mismatch cases.
These findings formed the basis for the current strategy in
regenerativemedicine to utilize homo-to-hetero transplan-
tation. However, whereas the regenerated CM transplants
required administration of an immune-suppressive agent
the regenerated RPM did not, inferring that the microenvi-
ronment of the retina, known as one of immune-privileged
sites, is more tolerant of allogeneic grafts.
Whereas the aforementioned monkey homo-to-hetero
transplantation experiments have provided important
information, from the viewpoint of the present study
criticism could be raised: KIR-ligand match or mismatch
was not taken into consideration in experimental design
and interpretation of data in these studies, which could
have influenced the outcomes. Further studies are required
to assess the involvement of KIR-ligand match/mismatch
in animal models.
As a practical clinical question, we estimated the
frequency at which KIR-ligand mismatch may occur at
the population level, if recipients are selected without
taking into consideration the status of KIR-ligand match-
ing, using the data of haplotype frequencies in the Japanese
as a test case (Ikeda et al., 2015). Because the allotype fre-
quencies of C1 versus C2 in Japanese is 92.7:7.3, most of
the HLA-homo iPSCs (if generated at random) will be of
the C1/C1 type. Indeed, among the HLA-homo iPSC lines
carrying the frequently observed top-10 HLA haplotypes,
only one (no. 6) is of the C2/C2 type (Table S3). In the
case of selecting recipients for HLA-homo-C1/C1 iPSC-
derived tissues, the frequency of C1/C2 recipients within
HLA-hetero recipients is predicted to be 7.3%. On the other
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hand, whenwe use HLA-homo-C2/C2 iPSC-derived tissues,
KIR-ligand mismatch will occur at 92.7%. Thus, in general
the frequency of KIR-ligand mismatch for HLA-C is rather
rare in homo-to-hetero transplantations in Japanese per-
sons. In contrast, the allotype frequency of C2 is much
higher in other populations, and the chances of a C1 or
C2 mismatch are thus considerably higher. For example,
in the Polish population the ratio of C1 to C2 is approxi-
mately 6:4 (Nowak et al., 2010). If a regenerated iPSC-
derived tissue is to be transplanted in this population, the
chances of a C1/C1 to C1/C2 mismatch is 40%, and a
C2/C2 to C1/C2 transplant will occur at 60% frequency.
Ligand frequencies of HLA alleles containing the Bw4
motif in Japanese (Tables S2 and S3) reveal a different pic-
ture. Among the HLA-A allele types, A*24:02, the most
frequentHLA-A allele in the Japanese population, generally
categorized in the A-Bw4 ligand group, was excluded from
this consideration, because KIR3DL1 has been shown to
bindHLA-A allotypes with the Bw4motif, but the signaling
does not seem to be strong enough to induce licensing of
KIR3DL1+ cells (Yawata et al., 2008). HLA-B Bw4 ligand fre-
quency is 31% (Table S4), with the dominant presence of
KIR3DL1 (99.2%) (Yawata et al., 2006). Consequently,
KIR-ligand mismatch will occur at 30.8% frequency
when an HLA-homo graft lacking a Bw4 ligand is trans-
planted into an HLA-hetero recipient. It should be noted
that, among the HLA-homo iPSC lines carrying the
top-10 frequent HLA haplotypes, seven of them lack the
HLA-B Bw4 ligand (nos. 3, 4, 5, 6, 8, 9, and 10) (Table S3)
(Ikeda et al., 2015). Therefore, KIR-ligand mismatch
regarding the Bw4 motif will take place at considerably
high frequency in the iPSC-stock project in the near future.
Since 40% of HLA haplotypes encode an HLA-B Bw4
ligand in most populations globally (Norman et al.,
2007), a KIR3DL1-HLA-Bw4 mismatch will likely occur at
similar frequencies elsewhere as well.
The A haplotype is one that carries most of the KIR
known to be involved in licensing (KIR2DL1, KIR2DL3,
KIR3DL1), and the receptors encoded by this haplotype
recognize the full range of KIR ligands (groups 1 and
2 HLA-C, and Bw4). Therefore, donors homozygous for
this haplotype are suitable in analyzing the effects of NK
cell licensing and recognition of missing self, and eluci-
dating the rejection mechanism of cells regenerated from
iPSCs. In this study, the five donors from whom NK cells
were derived were all homozygotes for the group A haplo-
type (Figures 3A and S3A). The Japanese population is high-
ly suitable for the scope of such mechanistic studies, as the
group A KIR haplotype is the predominant haplotype in
the population (Yawata et al., 2002).
The contributions from activating KIR in rejecting iPSC-
derived cells are as yet unclear. In our study, KIR2DS4 was
the only ‘‘activating KIR gene’’ present in our NK donors
(Hetero-1 to -5). The KIR2DS4 gene has subtypes; KIR2DS4F
carries the full length ofKIR2DS4 gene,whileKIR2DS4D is a
variant of the deleted form encoding a soluble (membrane-
unbound) form of the molecule (Maxwell et al., 2002).
Although subtype variations can be seen in the five NK
donors (Figures 3A and S3A), we thought that the contribu-
tion of KIR2DS4 in NK response to the regenerated cells is
minimal, if any, since NK cells from Hetero-3 and Hetero-
4 carrying the KIR2DS4F gene did not create a response
while those from Hetero-5 carrying KIR2DS4D did.
In addition, recent studies have suggested that the
strength of licensing and inhibitory signaling varies among
the alleles of KIR and the HLA allotypes (Yawata et al.,
2008). For example, variations in KIR3DL1/HLA-Bw4
subtypes have been shown to affect clinical outcomes,
such as in antibody-based immunotherapy against neuro-
blastoma (Forlenza et al., 2016) or in hematopoietic stem
cell transplantation against leukemia (Boudreau et al.,
2017). Such subtype differences will also need to be consid-
ered in the field of regenerative medicine.
In summary, our present study demonstrates that human
NK cells have the potential to reject iPSC-derived tissue in a
homo-to-hetero transplantation setting when KIR ligands
are mismatched. This has special relevance in the trans-
plantation of tissues derived from HLA-homozygous iPSCs
from cell banks. Nonetheless, we feel that transplantation
across a KIR-ligandmismatch need not be contraindicated.
This is because in homo-to-hetero transplantation cases,
immune-suppressive drugs will be more or less adminis-
trated to recipients to suppress the inevitable immune
reaction caused by minor histocompatibility mismatch. It
is likely that such drugs will have the additional effect of
suppressing NK cell-mediated responses. However, in KIR-
ligand ‘‘matched’’ cases, it may be possible to reduce the
use of immune-suppressive agents. This would benefit
recipients, since immune-suppressive agents are known
to increase the frequency of post-transplant malignancy
and infectious diseases. In this context, we can also propose
that agents with NK cell-suppressive action, such as myco-
phenolate mofetil, may be preferable in KIR-ligand-mis-
matched cases (Harmon et al., 2016; Ohata et al., 2011).
Finally, we propose that KIR-ligand matching should be
assessed in the coming homo-to-hetero transplantations
using HLA-homo iPSCs, and that KIR-ligand-mismatched




This study was approved by the institutional review board of the
Graduate School of Medicine, Kyoto University (approval number:
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specimens from healthy individuals were collected after written
informed consent was obtained.
Human Subjects
Blood samples were obtained from healthy, unrelated volunteer
donors after obtaining informed consent for sample procure-
ment as approved by Kyoto University Hospital. PBMCs were
isolated using Ficoll-Paque PLUS (GE Healthcare). CD8+ T cells
were isolated by positive selection using magnetic microbeads
(Miltenyi Biotec). NK cells were purified by positive selection
of CD56+ cells after negative selection of CD3+, CD4+, CD8+,
CD14+, and CD19+ cells with microbeads (Miltenyi Biotec).
The post-sort purity of NK cells (CD56+CD3) was >95% for all
experiments.
Plasmid Constructs
cDNA clones of HLA-C*04:01:01, HLA-C*15:02:01, and HLA-
C*01:02 cDNA genes were provided by the RIKEN BRC through
the National Bio-Resource Project of the MEXT, Japan, cloned by
methods described previously (Akatsuka et al., 2002).
HLA Typing and KIR Next-Generation Sequencing
Analysis
HLA and KIR typing were performed at the HLA Foundation
Laboratory (Kyoto, Japan). HLA typing was performed with
PCR-rSSOP using WAKFlow (Wakunaga Pharmaceutical). Next-
generation sequencing-based KIR typing used PCR-based amplifi-
cation of KIR and sequencing using Illumina MiSeq technology
as described by Nelson et al. (2015). In brief, the laboratory steps
consist of consecutive PCR reactions with barcoding for individ-
ual sample tracking. Robust assays for each of the target loci for
all KIR loci were developed. The depth of genotyping was
extended to all KIR loci to include exons 3, 4, 5, and 9. The
analytical tools to define haplotypes and genotypes were devel-
oped by Scisco Genetics (Seattle, WA). The HLA-C allele typing
results were classified according to the current C1, C2
classification.
Establishment of iPSCs
iPSCs from peripheral blood CD8+ T cells were established by the
method of Maeda et al. (2016) with slight modifications (see Sup-
plemental Experimental Procedures).
Lentivirus Preparation and Infection
Each cDNA clone of HLA-C allele was subcloned into the pENTR/
D-TOPO vector and further subcloned into an expression vector,
CS-UbC-RfA-IRES2-Venus (a gifted from Atsushi Miyawaki,
RIKEN) using pENTR Directional TOPO Cloning Kits (Thermo
Fisher Scientific). Lentiviruses were collected 48–72 hr after
transfection of Lenti-X 293T cells (Clontech) with appropriate
amounts of lentiviral vectors, pRSV-Rev, pMDLg/pRRE, and
pMD2.G (Addgene) using ViaFect (Promega). iPSCs (5 3 104)
were infected by centrifugation and seeded onto mouse embry-
onic fibroblasts with iPSC medium. Venus-expressing iPSC col-
onies were picked up manually and maintained in iPSC
medium.
Differentiation of iPSCs to CD8 Single-Positive T Cells
The following iPSC clones were differentiated into iPSC-TCs:
Homo-A#1 and Hetero-1#1. CD8 single-positive T cells derived
from iPSCs were differentiated using the method described by
Maeda et al. (2016) with slight modifications (see Supplemental
Experimental Procedures).
Differentiation of iPSCs to Vascular Endothelial Cells
The following iPSC clones were differentiated into iPSC-VEs:
Homo-A#1, Hetero-1#4, and 454E2. VE cells derived from iPSCs
were differentiated using the method of Masumoto et al. (2014)
with some modifications (see Supplemental Experimental
Procedures).
In Vitro Cytotoxicity Assay
Frozen NK cells were thawed and cultured for 12 hr with
RPMI with 10% human serum. NK cells were then used as
effector cells for 51Cr release assays against iPSC-TCs and
iPSC-VEs. A total of 4,000 51Cr-labeled cells were used as
target per well. In some experiments KIR2DL1+ or KIR2DL1
cells were isolated using anti-KIR2DL1 monoclonal
antibody conjugated with allophycocyanin (APC) and anti-APC
microbeads (Miltenyi Biotec) after thaw, and were cultured
for 12 hr. After 6 or 18 hr of co-culture, culture supernatant
was applied to Picoplate (PerkinElmer) and analyzed by
TopCount NXT (PerkinElmer). The percentage of specific
lysis was calculated as follows: specific lysis (%) = (sample lysis
with NK [%]  basal lysis without NK [%])/(100  basal lysis
without NK [%]).
CD107a Mobilization and Intracellular Cytokine
Assays
Freshly isolated NK cells were co-cultured with target at an 1:1 E/T
ratio for 12 hr in the presence of BD GolgiStop (BD Biosciences)
and Brefeldin A (Sigma). For measurement of degranulation by
NK cells, anti-CD107a was added in a 1:200 dilution to the co-cul-
tures. Cells were permeabilized with a BD Cytofix/Cytoperm Kit
(BD Biosciences). Flow cytometry was performed on a FACSCanto
II instrument.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2017.07.020.
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Supplemental Figure Legends 
 
Figure S1. NK cells do not respond to the cells regenerated from autologous iPSCs, 
related to Figure 1 
(A) Schematic illustration of the experimental procedure. An example where iPSCs 
were produced from Hetero-1. T cells or VE cells regenerated from the iPSCs were 
co-cultured with NK cells collected from donor Hetero-1, and the activation status of 
NK cells or cytotoxicity against regenerated cells was assessed. (B, C) 12 hours 
co-incubation assays. NK cells from Hetero-1 did not respond to Auto iPSC-TCs (B) 
and Auto iPSC-VEs (C) in terms of cytotoxicity (CD107a) and cytokine (IFN-γ) 
production. (D, E) 18 hours 51Cr release cytotoxicity assays using Hetero-1 NK cells 
against Auto iPSC-TCs (D) or Auto iPSC-VEs (E). Results are presented as mean±SD 
from three independent experiments. *p < 0.05, **p < 0.01, ***p<0.001; Student’s t 
test. 
 
Figure S2. KIR2DL1+ NK cell subsets isolated from a C1/C2 donor respond to 
regenerated C1/C1 T cells or VE cells, related to Figure 3  
(A, B) Representative flow cytometric profiles of CD107a (A) and IFN-γ(B) 
expression in each NK cell subset after co-culture with Auto iPSC-TCs or Homo-A 
iPSC-TCs for 12 hours. 
 
Figure S3. KIR-ligand mismatched NK cells respond to VE cells regenerated from 
 6 
iPSCs homozygous for the most frequent HLA haplotype in the Japanese, related 
to Figure 6 
(A) The KIR genotypes for the three donors from which NK cells were isolated are 
shown. The full and deleted forms of KIR2DS4 are indicated by an ‘F’ and ‘D’ 
respectively. (B) The R1-R4 subsets within the NK cells isolated from donor Hetero-3 
(left) and Hetero-4 (right), as defined by the expressed combinations of KIR2DL1 and 
KIR2DL3. (C, D) Frequency of CD107a (C) and IFN-γ (D) positive NK cells derived 
from Hetero-3 and Hetero-4 after co-culture with Auto PBMCs and 454E2-VEs for 12 

















Supplemental Table1, Characterization of pluripotency of iPSC lines. 
iPS line SSEA-3 SSEA-4 TRA-1-60 TRA-1-81 Nanog Oct3/4 teratoma 
Homo-A#1 + + + + + + + 
Hetero-1#1 + + + + + + + 
Hetero-1#4 + + + + + + + 

















Supplemental Table2, Assignment of KIR ligands. 
 
Alleles included Alleles excluded KIR 
Ligands 
Allele groups 
by motif by motif by function 
A-Bw4 1) A*23, A*24, A*25, A*32 A*31:08 A*24:04 A*25:01 2),3) 
B-Bw4 1) 
B*13, B*27, B*37, B*38, 
B*44, B*49, B*51, B*52, 
B*53, B*57, B*58, B*59 
B*07:36, B*08:02, B*08:03, 
B*15:13, B*15:16, B*15:17, 
B*15:23, B*15:24, B*40:13, 
B*40:19, B*47:01 
B*27:08, B*27:12, B*37:03N, B*44:09, 
B*44:15, B*47:02, B*47:03, B*51:50, 
B*53:05 
B*13:01, 
B*13:02 3), 4) 
C1 
C*01, C*03, C*07, C*08, 
C*12, C*14, C*16 
 C*03:07 (C2), C*03:10 (C2), C*07:07 (C2), 
C*08:10 (C2), C*12:04 (C2), C*12:05 (C2),  
C*12:09 (C2), C*16:02 (C2) 
 
C2 
C*02, C*04, C*05, C*06, 





1) Gumperz, J.E., Litwin, V., Phillips, J.H., Lanier, L.L., Parham, P., 1995. The Bw4 public epitope of HLA-B molecules confers 
reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. Journal of Experimental Medicine 181, 
1133–1144. 
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Supplemental Table3, Top 100 HLA haplotype frequencies in the Japanese. 
Rank A C B DRB1 Frequency A-Bw4 B-Bw4 C1 C2 
1 *24:02 *12:02 *52:01 *15:02 8.377% ○ ○ ○   
2 *33:03 *14:03 *44:03 *13:02 4.473%   ○ ○   
3 *24:02 *07:02 *07:02 *01:01 3.722% ○   ○   
4 *24:02 *01:02 *54:01 *04:05 2.539% ○   ○   
5 *02:07 *01:02 *46:01 *08:03 1.866%     ○   
6 *11:01 *04:01 *15:01 *04:06 1.345%       ○ 
7 *24:02 *01:02 *59:01 *04:05 1.058% ○ ○ ○   
8 *11:01 *01:02 *54:01 *04:05 1.001%     ○   
9 *26:01 *03:04 *40:02 *09:01 0.746%     ○   
10 *24:02 *08:01 *40:06 *09:01 0.709% ○   ○   
11 *24:02 *14:02 *51:01 *09:01 0.652% ○ ○ ○   
12 *31:01 *14:02 *51:01 *08:02 0.579%   ○ ○   
13 *33:03 *14:03 *44:03 *08:03 0.547%   ○ ○   
14 *26:02 *08:01 *40:06 *09:01 0.542%     ○   
15 *02:01 *03:04 *13:01 *12:02 0.532%     ○   
15 *24:02 *01:02 *46:01 *08:03 0.532% ○   ○   
17 *02:06 *08:01 *40:06 *09:01 0.464%     ○   
18 *11:01 *07:02 *39:01 *08:03 0.433%     ○   
19 *26:01 *03:04 *40:02 *08:02 0.428%     ○   
20 *02:06 *03:03 *35:01 *15:01 0.422%     ○   
21 *24:02 *12:02 *52:01 *09:01 0.391% ○ ○ ○   
21 *31:01 *14:02 *51:01 *14:03 0.391%   ○ ○   
23 *02:06 *07:02 *39:01 *15:01 0.386%     ○   
24 *24:02 *03:04 *40:02 *09:01 0.370% ○   ○   
25 *02:01 *01:02 *54:01 *04:05 0.360%     ○   
26 *26:03 *03:03 *15:01 *15:01 0.344%     ○   
27 *11:01 *07:02 *67:01 *16:02 0.339%     ○   
28 *02:06 *01:02 *59:01 *04:05 0.323%   ○ ○   
28 *24:02 *03:03 *15:07 *04:03 0.323% ○   ○   
30 *24:02 *07:04 *15:18 *04:01 0.318% ○   ○   
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31 *02:07 *01:02 *46:01 *09:01 0.308%     ○   
31 *33:03 *03:02 *58:01 *13:02 0.308%   ○ ○   
33 *26:01 *03:03 *35:01 *04:10 0.302%     ○   
34 *02:01 *03:03 *15:11 *09:01 0.292%     ○   
34 *24:02 *04:01 *15:01 *04:06 0.292% ○     ○ 
36 *24:02 *14:02 *51:01 *14:03 0.276% ○ ○ ○   
37 *24:02 *03:04 *40:01 *04:05 0.266% ○   ○   
38 *26:02 *03:03 *15:01 *14:06 0.261%     ○   
39 *24:02 *03:04 *40:02 *04:05 0.255% ○   ○   
40 *02:01 *07:02 *07:02 *01:01 0.250%     ○   
40 *02:06 *07:02 *07:02 *01:01 0.250%     ○   
42 *11:01 *01:02 *54:01 *08:03 0.240%     ○   
42 *11:01 *01:02 *55:02 *04:05 0.240%     ○   
42 *31:01 *14:02 *51:01 *04:05 0.240%   ○ ○   
45 *02:01 *15:02 *51:01 *15:01 0.235%   ○   ○ 
45 *03:01 *05:01 *44:02 *13:01 0.235%   ○   ○ 
45 *11:01 *07:02 *67:01 *15:01 0.235%     ○   
45 *24:02 *14:03 *44:03 *13:02 0.235% ○ ○ ○   
49 *01:01 *06:02 *37:01 *10:01 0.229%   ○   ○ 
49 *24:02 *03:03 *35:01 *15:01 0.229% ○   ○   
49 *24:02 *03:04 *40:01 *11:01 0.229% ○   ○   
49 *31:01 *14:02 *51:01 *09:01 0.229%   ○ ○   
53 *26:03 *03:03 *15:01 *09:01 0.224%     ○   
54 *02:06 *01:02 *54:01 *04:05 0.219%     ○   
54 *02:06 *03:03 *35:01 *09:01 0.219%     ○   
56 *02:01 *01:02 *46:01 *08:03 0.214%     ○   
56 *02:01 *08:01 *40:06 *09:01 0.214%     ○   
56 *02:06 *08:01 *48:01 *04:07 0.214%     ○   
56 *31:01 *04:01 *56:01 *09:01 0.214%       ○ 
60 *31:01 *07:02 *07:02 *01:01 0.209%     ○   
61 *24:02 *03:03 *35:01 *09:01 0.198% ○   ○   
61 *26:01 *07:02 *07:02 *01:01 0.198%     ○   
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63 *24:02 *03:04 *40:02 *15:01 0.193% ○   ○   
63 *24:02 *12:02 *52:01 *04:05 0.193% ○ ○ ○   
63 *31:01 *03:04 *40:02 *14:54 0.193%     ○   
66 *11:01 *03:03 *35:01 *04:05 0.188%     ○   
66 *24:02 *03:04 *40:01 *09:01 0.188% ○   ○   
66 *26:01 *01:02 *54:01 *04:05 0.188%     ○   
69 *24:02 *03:03 *35:01 *04:05 0.183% ○   ○   
69 *24:02 *08:03 *54:01 *04:05 0.183% ○   ○   
71 *02:01 *03:03 *35:01 *04:10 0.177%     ○   
71 *11:01 *12:02 *52:01 *15:02 0.177%   ○ ○   
71 *24:02 *08:01 *40:06 *12:01 0.177% ○   ○   
71 *31:01 *12:02 *52:01 *15:02 0.177%   ○ ○   
75 *02:01 *03:04 *40:01 *04:05 0.172%     ○   
75 *24:02 *01:02 *54:01 *08:03 0.172% ○   ○   
77 *02:06 *14:02 *51:01 *09:01 0.167%   ○ ○   
77 *24:02 *14:02 *51:01 *15:01 0.167% ○ ○ ○   
79 *02:01 *03:04 *40:02 *09:01 0.162%     ○   
79 *02:06 *07:02 *39:01 *08:02 0.162%     ○   
79 *02:10 *08:01 *40:06 *04:05 0.162%     ○   
82 *24:02 *01:02 *54:01 *13:01 0.156% ○   ○   
82 *24:02 *03:03 *35:01 *08:02 0.156% ○   ○   
82 *24:02 *03:04 *13:01 *12:02 0.156% ○   ○   
82 *24:02 *04:01 *40:01 *09:01 0.156% ○     ○ 
82 *24:02 *14:02 *51:01 *04:05 0.156% ○ ○ ○   
82 *26:01 *03:03 *35:01 *08:02 0.156%     ○   
82 *31:01 *14:02 *51:01 *14:05 0.156%   ○ ○   
89 *02:01 *07:02 *39:01 *15:01 0.151%     ○   
89 *02:01 *12:02 *52:01 *15:02 0.151%   ○ ○   
89 *02:01 *14:02 *51:01 *09:01 0.151%   ○ ○   
89 *02:06 *03:04 *40:02 *08:02 0.151%     ○   
89 *26:01 *12:02 *52:01 *15:02 0.151%   ○ ○   
89 *30:01 *06:02 *13:02 *07:01 0.151%       ○ 
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95 *02:01 *03:03 *15:01 *09:01 0.146%     ○   
95 *02:06 *12:02 *52:01 *15:02 0.146%   ○ ○   
97 *02:01 *01:02 *55:02 *04:05 0.141%     ○   
97 *24:02 *01:02 *54:01 *09:01 0.141% ○   ○   
97 *24:02 *03:04 *40:02 *08:02 0.141% ○   ○   
97 *24:02 *03:04 *40:02 *14:54 0.141% ○   ○   
97 *24:02 *15:02 *40:06 *09:01 0.141% ○     ○ 
97 *31:01 *01:02 *54:01 *04:05 0.141%     ○   
97 *31:01 *03:04 *40:02 *08:02 0.141%     ○   

















Supplemental Table4, Summery of KIR ligands frequencies in the Japanese. 
 Bw4 
Rank A-Bw4 B-Bw4 
C1 C2 Frequency 
1     ○   41.09% 
2 ○   ○   21.54% 
3   ○ ○   14.75% 
4 ○ ○ ○   13.86% 
5       ○ 4.74% 
6   ○   ○ 2.08% 
7 ○     ○ 1.49% 
8 ○ ○   ○ 0.39% 
9     ○ ○ 0.03% 
10 ○   ○ ○ 0.02% 















Supplemental Experimental Procedures 
Establishment of iPSCs  
CD8+ T cells were enriched by CD8 microbeads (Miltenyi Biotec) from freshly isolated 
PBMCs. 1x106 enriched CD8+ T cells were stimulated overnight by human T-Activator 
CD3/CD28 Dynabeads (life technologies). Next day, cells were transduced with Sendai 
virus vectors containing the four Yamanaka factors (Nishimura et al., 2011) and SV40 
large T antigen (LTa) (Addgene) at MOI 3. Following 2 hours incubation at 37℃, cells 
were seeded onto murine embryonic fibroblasts (MEF) feeder cells and cultured in 
RPMI-1640 supplemented with 10% human AB Serum. From at day 2, half of the 
medium was replaced with human iPSC medium, Repro Stem (REPROCELL) 
supplemented with 5 ng/ml basic fibroblast growth factor (bFGF; Wako). Colonies 
started to appear from 20-35 days. Each colony was picked up and expanded. All iPSC 
clones were maintained in iPSC medium. Following iPSC clones were used: Homo-A#1, 
Hetero-1#1 and Hetero-1#4. 
  
Differentiation of iPS cells to CD8 single positive T cells 
iPSCs were differentiated into CD8 single positive T cells using the OP9 and 
OP9/DLL1 stromal cell co-culture systems as described previously (Maeda et al., 2016; 
Vizcardo et al., 2013). In brief, about 600 human iPSC clumps were plated on gelatin 
pre-coated OP9 overconfluent 10 cm dishes filled with 10 ml of OP9 medium, i.e. 
α-MEM (Invitrogen) with 20% FCS, penicillin (100 U/mL), streptomycin (100 μg/mL). 
On the next day, medium was replaced by 20 ml of fresh medium and thereafter 
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changed every 4 days. On day 13, colonies were treated for 45 minutes with 10 ml of 
collagenase Type IV (50 U/ml) (Invitrogen) and subsequently dissociated for 30 
minutes at 37°C using trypsin-EDTA (0.05%) (Nacalai tesque). To remove stromal cells, 
dissociated cells were resuspended by adding 5 times v/v OP9 medium and then plated 
on plastic at 37°C for one hour and floating cells were collected. To remove any 
remaining stromal cells and aggregated cells, the cell suspensions were passed through a 
100 μm filter. Cells were plated in an OP9/DLL1 semi-confluent dish on OP9 medium 
containing hIL-7 (5 ng/ml), hFlt-3L (5 ng/ml), and hSCF (5 ng/ml). On day 3, 
semi-adherent cells were collected and passage into a new dish layered with OP9/DLL1 
cells. From this point, passage was done every 7 days. On day 28, floating cells were 
collected after seeding on OP9/DLL1. CD4/8 DP cells were enriched by using CD4 
microbeads (Miltenyi Biotec) according to the manufacturer’s protocol. DP cells were 
stimulated with CD3 Ab (50 ng/ml) (OKT-3) purchased from eBioscience in the 
presence of hIL-2 (100 U/ml) and hIL-7 (5 ng/ml). 
  
Differentiation of iPS cells to vascular endothelial cells 
iPSCs were seeded onto Laminin-511-coated plates at a density of 100,000 cells/cm2 in 
Stem Fit AK02N (REPROCELL) with 4 ng/mL bFGF for 2–3 days before induction. 
To induce cardiac differentiation, we replaced Stem Fit AK02N with RPMI+B27 
medium (RPMI1640, 2 mM L-glutamine, 1× B27 supplement without insulin) 
supplemented with 125 ng/ml of Activin A (R&D) for 18 hours, followed by 10 ng/ml 
human bone morphogenetic protein 4 (BMP4; R&D) and 10 ng/ml bFGF for 4 days 
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without culture medium change. The culture medium was subsequently replaced with 
RPMI+B27 medium supplemented with 100 ng/ml of VEGF165 (WAKO), and culture 
medium was refreshed every other day. Cells were collected by Accumax (Innovative 
Cell Technologies) and CD31+VE-cadherin+ cells were sorted by FACS AriaⅢ. Isolated 
VE cells were seeded onto fibronectin (TaKaRa) coated plates at a density of 45,000 




Severe combined immune-deficient (SCID) mice were injected with 1×106 human 
iPSCs subcutaneously. Twelve weeks after injection, tumors were resected, fixed in 
10% formaldehyde and embedded in paraffin. Sections were stained with hematoxylin 
and eosin and examined histologically. 
 
Flow cytometry 
The following monoclonal antibodies were used. CD3 (HIT3a, #300318), CD4 
(RPA-T4, #300508), CD8 (HIT8a, #300928), CD31 (WM59, #303109), CD56 (B159, 
#560842), CD107a (H4A3, #562623), VE-Cadherin (16B1, #12-1449-80), HLA class I 
(W6/32, #311409), TCRαβ (IP26, #306720), IFN-γ (4S.B3, #502528), KIR2DL1 
(143211, #FAB1844A), KIR2DL3 (180701, #FAB2014P), SSEA-3 (MC-631, #560236), 
SSEA-4 (MC813-70, #560126), TRA-1-60 (TRA-1-60, #560193), TRA-1-81 
(TRA-1-81, #560161), Nanog (N31-355, #560483), Oct3/4 (40/Oct-3, #560253). All 
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Abs were purchased from BioLegend, BD Biosciences, eBioscience or R&D Systems. 
Flow cytometry was performed using a FACSCanto II or FACSAriaIII (BD) and the 
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